RxDoctor Payments Data

Byron Lake, MD

Family Medicine · Grass Valley, CANPI 1891832242

Payments from drug & device makers

$423in general payments, 2019–2025

Across 18 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$114
  • AbbVie$54
  • Merck$33
  • GSK$31
  • Takeda Pharmaceuticals U.S.A., Inc.$24
  • Amarin Pharma, Inc.$23
  • plus $143 from 8 others

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$423 in reported general payments places this provider in the 60th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$199,241
Medicare patients
529
Services billed
2,389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$99,687
JardianceEmpagliflozin45$55,669
OzempicSemaglutide22$31,058
VeltassaPatiromer Calcium Sorbitex11$10,814
Pitavastatin Calcium16$8,773
SymbicortBudesonide/Formoterol Fumarate19$6,864
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,825
Atorvastatin Calcium562$6,079
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen203$5,272
Incruse ElliptaUmeclidinium Bromide14$5,029
Tamsulosin Hcl237$3,449
Testosterone21$3,087
Levothyroxine Sodium199$2,858
Metoprolol Succinate148$2,584
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$99,687121 claims
Novo NordiskOzempic$114$31,05822 claims
GSKTrelegy Ellipta, Incruse Ellipta$31$11,85425 claims
AbbVieSynthroid$54$1,99821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,533 family medicine providers in California.

Other family medicine in Grass Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →